Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically confirmed malignant solid tumor with metastatic disease. * Presence of more than five and up to ten (6-10) extracranial metastatic lesions, identified on CT or PET/CT imaging and assessable by RECIST version 1.1 (and/or PERCIST when PET imaging is used). * At least one metastatic lesion considered suitable for image-guided iodine-125 (125I) seed implantation according to institutional assessment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Adequate organ function to undergo interventional procedures and systemic therapy, as determined by institutional standards. * Ability to understand and willingness to provide written informed consent. Exclusion Criteria: * Diffuse or unstable central nervous system involvement, including leptomeningeal disease or uncontrolled/symptomatic brain metastases requiring immediate local intervention. * Medical conditions that preclude safe interventional procedures, including uncontrolled infection, severe cardiopulmonary dysfunction, or other serious systemic illness, as judged by the investigator. * Contraindications to percutaneous implantation, such as uncorrectable coagulation disorders, high bleeding risk, lack of a safe needle path, or unacceptable risk to critical organs. * Pregnancy or breastfeeding. * Inability to provide informed consent or comply with study procedures, due to severe psychiatric illness, cognitive impairment, or other limiting conditions. * Any other condition that, in the investigator's judgment, would make the patient unsuitable for study participation or compromise patient safety or study integrity.